204 related articles for article (PubMed ID: 28877629)
1. Application of chimeric antigen receptor-engineered T cells in ovarian cancer therapy.
Zhang M; Zhang DB; Shi H
Immunotherapy; 2017 Sep; 9(10):851-861. PubMed ID: 28877629
[TBL] [Abstract][Full Text] [Related]
2. Prospects of chimeric antigen receptor T cell therapy in ovarian cancer.
Jindal V; Arora E; Gupta S; Lal A; Masab M; Potdar R
Med Oncol; 2018 Apr; 35(5):70. PubMed ID: 29651744
[TBL] [Abstract][Full Text] [Related]
3. Adnectin-Based Design of Chimeric Antigen Receptor for T Cell Engineering.
Han X; Cinay GE; Zhao Y; Guo Y; Zhang X; Wang P
Mol Ther; 2017 Nov; 25(11):2466-2476. PubMed ID: 28784559
[TBL] [Abstract][Full Text] [Related]
4. Current strategies to improve the safety of chimeric antigen receptor (CAR) modified T cells.
Yang QY; Yang JD; Wang YS
Immunol Lett; 2017 Oct; 190():201-205. PubMed ID: 28837818
[TBL] [Abstract][Full Text] [Related]
5. Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo.
Lanitis E; Poussin M; Klattenhoff AW; Song D; Sandaltzopoulos R; June CH; Powell DJ
Cancer Immunol Res; 2013 Jul; 1(1):43-53. PubMed ID: 24409448
[TBL] [Abstract][Full Text] [Related]
6. Tumor-targeting domains for chimeric antigen receptor T cells.
Bezverbnaya K; Mathews A; Sidhu J; Helsen CW; Bramson JL
Immunotherapy; 2017 Jan; 9(1):33-46. PubMed ID: 28000526
[TBL] [Abstract][Full Text] [Related]
7. Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy.
O'Hara M; Stashwick C; Haas AR; Tanyi JL
Immunotherapy; 2016; 8(4):449-60. PubMed ID: 26973126
[TBL] [Abstract][Full Text] [Related]
8. Possible Compartmental Cytokine Release Syndrome in a Patient With Recurrent Ovarian Cancer After Treatment With Mesothelin-targeted CAR-T Cells.
Tanyi JL; Stashwick C; Plesa G; Morgan MA; Porter D; Maus MV; June CH
J Immunother; 2017 Apr; 40(3):104-107. PubMed ID: 28234665
[TBL] [Abstract][Full Text] [Related]
9. Chimeric antigen receptor-redirected T cells return to the bench.
Geldres C; Savoldo B; Dotti G
Semin Immunol; 2016 Feb; 28(1):3-9. PubMed ID: 26797495
[TBL] [Abstract][Full Text] [Related]
10. Prospects to improve chimeric antigen receptor T-cell therapy for solid tumors.
Jin C; Yu D; Essand M
Immunotherapy; 2016 Dec; 8(12):1355-1361. PubMed ID: 28000533
[TBL] [Abstract][Full Text] [Related]
11. CAR T-cell therapy of solid tumors.
Yong CSM; Dardalhon V; Devaud C; Taylor N; Darcy PK; Kershaw MH
Immunol Cell Biol; 2017 Apr; 95(4):356-363. PubMed ID: 28003642
[TBL] [Abstract][Full Text] [Related]
12. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
[TBL] [Abstract][Full Text] [Related]
13. Current status and regulatory perspective of chimeric antigen receptor-modified T cell therapeutics.
Kim MG; Kim D; Suh SK; Park Z; Choi MJ; Oh YK
Arch Pharm Res; 2016 Apr; 39(4):437-452. PubMed ID: 26895243
[TBL] [Abstract][Full Text] [Related]
14. Overcoming barriers of car T-cell therapy in patients with mesothelin-expressing cancers.
O'Hara MH; Stashwick C; Plesa G; Tanyi JL
Immunotherapy; 2017 Aug; 9(9):767-780. PubMed ID: 28771103
[TBL] [Abstract][Full Text] [Related]
15. Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects.
Di S; Li Z
Sci China Life Sci; 2016 Apr; 59(4):360-9. PubMed ID: 26968709
[TBL] [Abstract][Full Text] [Related]
16. Adverse Effects Associated with Clinical Applications of CAR Engineered T Cells.
Badieyan ZS; Hoseini SS
Arch Immunol Ther Exp (Warsz); 2018 Aug; 66(4):283-288. PubMed ID: 29427174
[TBL] [Abstract][Full Text] [Related]
17. Functional comparison of engineered T cells carrying a native TCR versus TCR-like antibody-based chimeric antigen receptors indicates affinity/avidity thresholds.
Oren R; Hod-Marco M; Haus-Cohen M; Thomas S; Blat D; Duvshani N; Denkberg G; Elbaz Y; Benchetrit F; Eshhar Z; Stauss H; Reiter Y
J Immunol; 2014 Dec; 193(11):5733-43. PubMed ID: 25362181
[TBL] [Abstract][Full Text] [Related]
18. 'Atypical' CAR T cells: NKG2D and Erb-B as examples of natural receptor/ligands to target recalcitrant solid tumors.
Gilham DE; Maher J
Immunotherapy; 2017 Aug; 9(9):723-733. PubMed ID: 28771104
[TBL] [Abstract][Full Text] [Related]
19. The promise and potential pitfalls of chimeric antigen receptors.
Sadelain M; Brentjens R; Rivière I
Curr Opin Immunol; 2009 Apr; 21(2):215-23. PubMed ID: 19327974
[TBL] [Abstract][Full Text] [Related]
20. Adoptive immunotherapy for hematological malignancies: Current status and new insights in chimeric antigen receptor T cells.
Allegra A; Innao V; Gerace D; Vaddinelli D; Musolino C
Blood Cells Mol Dis; 2016 Nov; 62():49-63. PubMed ID: 27865176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
